Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: Implication for subgroup selection for induction chemotherapy

Sung Hee Lim, Su Jin Lee, Myung Ju Ahn, Keunchil Park, Jong Mu Sun

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Objective: The purpose of this study is to compare the long-term clinical outcome of hypopharynx cancer and oropharynx cancer treated with concurrent chemoradiotherapy. Methods: A total of 213 patients with locally advanced hypopharyngeal squamous cell carcinoma (n = 79) or oropharygeal squamous cell carcinoma (n = 134) were included. All patients were treated with upfront concurrent chemoradiotherapy between 1995 and 2012. Results: The median overall survival and progression-free survival differed significantly between the two groups (P < 0.05). Overall survival and progression-free survival rates at 3 years were 52% and 42% for hypopharynx cancer, and 75% and 72% for oropharynx cancer, respectively. There was no significant difference in the overall incidence of distant metastases but more locoregional recurrences occurred in patients with hypopharynx cancer compared with those with oropharynx cancer with a statistical significance (P < 0.001). Conclusions: Patients diagnosed with locally advanced hypopharyngeal had relatively poor survival after upfront concurrent chemoradiotherapy. More intensive treatment such as induction chemotherapy before concurrent chemoradiotherapy might be needed to improve survival outcome in this subgroup of patients.

Original languageEnglish
Pages (from-to)40-45
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume46
Issue number1
DOIs
StatePublished - 1 Jan 2016

Keywords

  • Concurrent chemoradiotherapy
  • Hypopharynx cancer
  • Induction chemotherapy
  • Oropharynx cancer

Fingerprint

Dive into the research topics of 'Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: Implication for subgroup selection for induction chemotherapy'. Together they form a unique fingerprint.

Cite this